How does ICER plan to find out whether or not well being plans supply truthful entry to prescribed drugs? I summarized their method final 12 months as outlined of their white paper titled “Cornerstones of ‘Truthful’ Drug Protection: Acceptable Price-Sharing and Utilization Administration Insurance policies for Prescribed drugs.” Final month, closing protocol for his or her “Obstacles to Truthful Entry Evaluation“. Whereas the method follows their earlier protocol and white paper, not all all the factors on this white paper are being evaluated. Which standards is ICER evaluating? I’ve summarized the factors ICER plans to incorporate and exclude of their “Truthful Entry” evaluation under.
